These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8409337)

  • 1. Chronic non-A, non-B hepatitis complicated by end-stage renal failure treated with recombinant interferon alpha.
    Ellis ME; Alfurayh O; Halim MA; Sieck JO; Ali MA; Bernvil SS; Ali H; Barri Y; Ayub A; al-Fadda M
    J Hepatol; 1993 Jun; 18(2):210-6. PubMed ID: 8409337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C.
    Lampertico P; Rumi M; Romeo R; Craxì A; Soffredini R; Biassoni D; Colombo M
    Hepatology; 1994 Jan; 19(1):19-22. PubMed ID: 7506225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon treatment of chronic active hepatitis C in patients with end-stage chronic renal failure.
    Ozyilkan E; Simşek H; Uzunalimoğlu B; Telatar H
    Nephron; 1995; 71(2):156-9. PubMed ID: 8569947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
    Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
    J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled trial of recombinant human alpha-interferon therapy for chronic non-A, non-B (type C) hepatitis.
    Di Bisceglie AM; Martin P; Kassianides C; Lisker-Melman M; Goodman Z; Banks SM; Hoofnagle JH
    J Hepatol; 1990; 11 Suppl 1():S36-42. PubMed ID: 2127786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-alpha 2b treatment of chronic hepatitis C in haemodialysis patients.
    Raptopoulou-Gigi M; Spaia S; Garifallos A; Xenou P; Orphanou H; Zarafidou E; Petridou P; Vrettou H; Vagionas G; Galaktidou G
    Nephrol Dial Transplant; 1995 Oct; 10(10):1834-7. PubMed ID: 8592590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
    Alsaran K; Sabry A; Molhem A
    Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose leukocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C.
    Benci A; Caremani M; Menchetti D; Sasdelli M; Giusti PB
    Curr Med Res Opin; 1998; 14(3):141-4. PubMed ID: 9787979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha in chronic hepatitis C infection in dialysis patients.
    Huraib S; Tanimu D; Romeh SA; Quadri K; Al Ghamdi G; Iqbal A; Abdulla A
    Am J Kidney Dis; 1999 Jul; 34(1):55-60. PubMed ID: 10401016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: long-term outcome and effect of increased interferon doses in non-responders.
    Schvarcz R; Glaumann H; Weiland O; Norkrans G; Wejstål R; Frydén A
    Scand J Infect Dis; 1991; 23(4):413-20. PubMed ID: 1957127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alpha therapy in patients with chronic type C hepatitis: changes of serum ALT, anti-HCV & HCV-RNA.
    Cho HJ; Dong SH; Lee MS; Kim HY; Park CK; Yoo JY; Polito A; Quan S; Han JH
    Korean J Intern Med; 1992 Jan; 7(1):13-7. PubMed ID: 1282364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
    Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study.
    Vogel W; Graziadei I; Umlauft F; Datz C; Hackl F; Allinger S; Grünewald K; Patsch J
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):81S-85S. PubMed ID: 9011481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant interferon-alfa therapy in children with chronic hepatitis C.
    Bortolotti F; Giacchino R; Vajro P; Barbera C; Crivellaro C; Alberti A; Nebbia G; Zancan L; De Moliner L; Bertolini A
    Hepatology; 1995 Dec; 22(6):1623-7. PubMed ID: 7489965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and tolerance of interferon-alpha 2b in the treatment of chronic hepatitis C in haemodialysis patients.
    Pol S; Thiers V; Carnot F; Zins B; Roméo R; Berthelot P; Bréchot C
    Nephrol Dial Transplant; 1996; 11 Suppl 4():58-61. PubMed ID: 8918758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A histopathological study of the effects of 6-month versus 12-month interferon alpha-2b therapy in chronic hepatitis C.
    Ziol M; Nhieu JT; Roudot-Thoraval F; Métreau JM; Deugnier Y; Dhumeaux D; Zafrani ES
    J Hepatol; 1996 Dec; 25(6):833-41. PubMed ID: 9007710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.
    Causse X; Godinot H; Chevallier M; Chossegros P; Zoulim F; Ouzan D; Heyraud JP; Fontanges T; Albrecht J; Meschievitz C
    Gastroenterology; 1991 Aug; 101(2):497-502. PubMed ID: 1906028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy.
    Sikole A; Dzekova P; Selja N; Gaseva M; Nikolov IG; Zabzun M; Muharemi S; Asani A; Amitov V; Mena S; Grunevska V; Ivanovski L; Polenakovic M
    Ren Fail; 2007; 29(8):961-6. PubMed ID: 18067041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C?
    Potthoff A; Wiegand J; Lüth JB; Wedemeyer H; Manns MP; Tillmann HL
    Clin Nephrol; 2005 Mar; 63(3):232-5. PubMed ID: 15786827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.
    Shiffman ML; Hofmann CM; Thompson EB; Ferreira-Gonzalez A; Contos MJ; Koshy A; Luketic VA; Sanyal AJ; Mills AS; Garrett CT
    Hepatology; 1997 Sep; 26(3):780-5. PubMed ID: 9303513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.